NCT05864014

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 213 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.

Conditions

• Chemotherapy-Induced Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Hetrombopag	Hetrombopag
DRUG	Hetrombopag plus Placebo	Hetrombopag plus Placebo
DRUG	Placebo	Placebo

Timeline

• Start date: 2023-04-25
• Primary completion: 2025-03-03
• Completion: 2025-09-01
• First posted: 2023-05-18
• Last updated: 2025-04-16

Locations

1 site across 1 country: China